Table 3.
Economic evaluation of the main COVID-19 clinical pathway, with the inclusion of Rehabilitation costs
| Clinical Pathway | Economic evaluation of the hospital clinical pathway [€] |
Rehabilitation clinical pathway [€] |
Total costs (Hospital pathway + Rehabilitation clinical pathway) [€] |
Rehabilitation pathway impact on total costs [%] |
|---|---|---|---|---|
|
Clinical Pathway #1 (5.38% of patients) |
17,629.63€ | 5,802.00€ | 23,431.63€ | 24.76% |
|
Clinical Pathway #2 (15.84% of patients) |
10,941.41€ | 2,960.60€ | 13,902.01€ | 21.30% |
|
Clinical Pathway #3 (8.34% of patients) |
26,339.20€ | 5,802.00€ | 32,141.20€ | 18.05% |
|
Clinical Pathway #4 (29.06% of patients) |
10,778.04€ | 0.00€ | 10,778.04€ | 0.00% |
|
Clinical Pathway #5 (11.67% of patients) |
22,857.28€ | 2,960.60€ | 25,817.88€ | 11.47% |
|
Pathway #6 (9.01% of patients) |
3,421.47€ | 0.00€ | 6,198.02€ | 0.00% |
|
Pathway #7 (16.91% of patients) |
3,717.33€ | 2,960.60€ | 10,113.13€ | 29.27% |
|
Pathway #8 (3.79% of patients) |
8,900.42€ | 5,802.00€ | 21,346.32€ | 27.18% |